Investigational Eye Drops (NPDR-01)
Phase 1Small molecule
Investigational Eye Drops (NPDR-01) is one of 5 small molecule programs targeting Non-Proliferative Diabetic Retinopathy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Non-Proliferative Diabetic Retinopathy
#DrugCompanyPhaseTrials
1Lucentis
RocheApproved
Eylea
RegeneronApproved
Decadron
QQuince Therapeutics S.p.A.
Phase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Investigational Eye Drops (NPDR-01)
SSichuan Academy of Medical Sciences
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details